Sunday 18 October 2026 Export RLMD’s income statement to Excel — free account

Relmada Therapeutics, Inc.

In the quarter to June 2026, EPS grew 63.3% and free cash flow fell 50.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.10 0.10 −3.13%

Follow RLMD

Alert me

Market cap: $341.3M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 4.03

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	4	2	—	—	—	—	—	—	—	—	2	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 17.43%

Capital & Financial Ratios $m

Market Cap 341.34

Revenue —

Net Income (61.93)

Free Cash Flow (45.99)

Net Debt (217.73)

Current Ratio 29.52

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.69

Past 5Y EPS Growth —

This Y EPS Growth 57.07%

Next Y EPS Growth (28.11%)

Next Y revenue growth —

Next 5Y EPS Growth 20.09%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 27.34%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	96	45	93	218
Receivables	—	—	—	0
Inventory	—	—	—	—
Other	—	—	—	—
	98	46	94	219

	2023	2024	2025	Q'26
Payables	4	4	2	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	12	10	6	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	50.41%	(3.91%)	(14.91%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(10)	—	—	—
’25	(18)	(6)	(7)	(15)	(46)
’24	(13)	(13)	(17)	(9)	(52)
’23	(17)	(13)	(12)	(10)	(52)
’22	(19)	(22)	(27)	(36)	(104)
’21	(16)	(17)	(21)	(38)	(92)
’20	(3)	(5)	(13)	(7)	(28)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(10)	—	—	—
’25	(18)	(6)	(7)	(15)	(46)
’24	(13)	(13)	(17)	(9)	(52)
’23	(51)	(13)	(12)	(10)	(52)
’22	(45)	(22)	(27)	(36)	(104)
’21	(37)	(17)	(21)	(38)	(92)
’20	(3)	(5)	(13)	(7)	(28)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.22)	(0.11)	—	—	—
’25	(0.58)	(0.30)	(0.30)	(0.27)	(1.45)
’24	(0.72)	(0.59)	(0.72)	(0.62)	(2.65)
’23	(0.87)	(0.84)	(0.73)	(0.84)	(3.28)
’22	(1.40)	(1.33)	(1.31)	(1.26)	(5.30)
’21	(1.34)	(1.56)	(2.44)	(1.80)	(7.16)
’20	(0.72)	(0.73)	(1.05)	(1.28)	(3.81)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.44	2.52	2.44	4.60	23.25	16.34	1.81	2.00	0.34	0.24	Analyst estimates 2026–2028 Powerpack
	High	16.40	5.60	7.76	48.00	54.00	40.00	38.68	4.85	7.22	5.12
People
People	Employees	6	3	3	4	14	10	14	20	17	17
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	EBT	(3)	(6)	(9)	(15)	(59)	(126)	(157)	(99)	(80)	(57)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(3)	(6)	(9)	(15)	(59)	(126)	(157)	(99)	(80)	(57)
	Depreciation	0	0	0	0	0	0	—	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(1.04)	(2.08)	(2.84)	(1.62)	(3.81)	(7.16)	(5.30)	(3.28)	(2.65)	(1.45)
	Cash flow	(4.53)	(2.14)	(1.91)	(1.31)	(1.78)	(5.23)	(3.50)	(1.72)	(1.72)	(1.16)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(4.53)	(2.14)	(1.91)	(1.31)	(1.78)	(5.23)	(3.50)	(1.72)	(1.72)	(1.16)
	Book value	2.43	0.48	(1.76)	12.52	6.77	11.87	4.74	2.84	1.18	2.19
	Shares, m	3	3	3	9	16	18	30	30	30	39
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(13)	(6)	(6)	(12)	(28)	(92)	(104)	(52)	(52)	(46)
	Capex	(1)	0	0	—	—	—	—	—	—	—
	Free cash flow	(13)	(6)	(6)	(12)	(28)	(92)	(104)	(52)	(52)	(46)
Balance, $m
Balance, $m	Working capital	6	1	(3)	115	105	208	140	85	36	88
	Total debt	0	0	3	0	—	—	—	—	—	—
	Net debt	(9)	(2)	(2)	(116)	(117)	(212)	(148)	(96)	(45)	(93)
	Shareholders’ equity	7	1	(6)	116	106	208	140	85	36	87
Returns, %
Returns, %	ROA	(29.04)	(221.60)	(293.98)	(23.56)	(50.53)	(73.64)	(83.48)	(78.89)	(111.57)	(82.08)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(42.24)	(430.49)	162.54	(24.34)	(53.74)	(80.14)	(90.07)	(87.51)	(132.33)	(94.05)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AVIR Atea Pharmaceuticals, Inc.	$363.3M	— (loss-making)	— (loss-making)	+295.16% (above 0%: growing)	n/m	+85.53% (above 0%: growing)	0.00%	0.00%	Compare
FENC Adherex Technologies Inc.	$362.9M	— (loss-making)	31.4×	+85.18% (above 0%: growing)	n/m	+101.36% (above 0%: growing)	95.97%	9.72%	Compare
TTRX Turn Therapeutics Inc.	$345.3M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
OBIO Orchestra BioMed Holdings, Inc.	$345.0M	— (loss-making)	— (loss-making)	−89.47% (below 0%: shrinking)	n/m	−25.87% (below 0%: shrinking)	71.59%	(25,404.55%)	Compare
CCCC C4 Therapeutics, Inc.	$342.0M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	+86.84% (above 0%: growing)	100.00%	(397.88%)	Compare
RLMD Relmada Therapeutics, Inc.	$341.3M	— (loss-making)	—	—	n/m	−50.06% (below 0%: shrinking)	0.00%	0.00%
IRD Opus Genetics, Inc.	$336.9M	— (loss-making)	— (loss-making)	−73.80% (below 0%: shrinking)	n/m	−16.37% (below 0%: shrinking)	100.00%	(2,182.78%)	Compare
ENTA Enanta Pharmaceuticals, Inc.	$334.1M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)	Compare
CYPH Cypherpunk Technologies Inc.	$325.5M	4.4×	— (loss-making)	0.00%	n/m	+15.53% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$343.5M	—	—	0.00%	—	−0.42%	95.97%	(60.02%)

All 614 Biotechnology stocks →

Relmada Therapeutics, Inc. (RLMD) key facts

Relmada Therapeutics, Inc. (RLMD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RLMD traded at $3.10, a market capitalization of $341.3 million.
Return on equity was −94.1% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.